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Abstract
A critical need still remains for effective delivery of RNA interference (RNAi) therapeutics to
target tissues and cells. Self-assembled lipid- and polymer-based systems have been most
extensively explored for transfection with small interfering RNA (siRNA) in liver and cancer
therapies. Safety and compatibility of materials implemented in delivery systems must be ensured
to maximize therapeutic indices. Hydrogel nanoparticles of defined dimensions and compositions,
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prepared via a particle molding process that is a unique off-shoot of soft lithography known as
PRINT (Particle Replication in Non-wetting Templates), were explored in these studies as
delivery vectors. Initially, siRNA was encapsulated in particles through electrostatic association
and physical entrapment. Dose-dependent gene silencing was elicited by PEGylated hydrogels at
low siRNA doses without cytotoxicity. To prevent disassociation of cargo from particles after
systemic administration or during post-fabrication processing for surface functionalization, a
polymerizable siRNA pro-drug conjugate with a degradable, disulfide linkage was prepared.
Triggered release of siRNA from the prodrug hydrogels was observed under a reducing
environment while cargo retention and integrity were maintained under physiological conditions.
Gene silencing efficiency and cytocompatibility were optimized by screening the amine content of
the particles. When appropriate control siRNA cargos were loaded into hydrogels, gene
knockdown was only encountered for hydrogels containing releasable, target-specific siRNAs,
accompanied by minimal cell death. Further investigation into shape, size, and surface decoration
of siRNA-conjugated hydrogels should enable efficacious targeted in vivo RNAi therapies.
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Introduction
Gene silencing via RNA interference (RNAi)1,2 has demonstrated great potential for the
treatment of diseases3,4 by halting the production of target proteins. The major challenge in
realizing the potential of RNAi therapies resides in delivering small interfering RNA
(siRNA) effectively to the cytoplasm of a target cell. With a highly negatively charged
backbone and a molecular weight of ca. 13 kDa, siRNA is unable to effectively cross cell
membranes without assistance. Additionally, siRNA is susceptible to degradation by
ubiquitous RNases in serum. A suitable carrier is required to enhance stability and facilitate
delivery to the cytoplasm of cells. Exemplar carriers include oligonucleotide conjugates5-14,
polyplexes8,15-18, and lipoplexes19-22. After systemic administration, the siRNA carrier
encounters several biological hurdles en route to the target tissue and cell such as clearance
by the reticuloendothelium system, protein fouling, and size requirements to reach particular
tissues. Designing delivery vehicles with surface decorations including stealthing (e.g.
polyethylene glycol, PEG23) and targeting (e.g. peptide13) ligands may promote prolonged
circulation and passive delivery to tissues of interest followed by actively targeting cell
surface receptors for internalization by desired cells.
Hydrogels and nanogels have been explored as delivery vector candidates for transfection of
cells with siRNA. Effective gene knockdown in kidney, epithelial, ovarian, and hepatoma
cell lines has been achieved by siRNA-associated hydrogels and nanogels24-28. Due to their
robust and tunable mechanical properties, hydrogel micro- or nano-particles may enable
delivery of siRNA to a wide range of tissues in vivo including delivery to circulating cells.
Bottom-up approaches for encapsulating siRNA in nanogels through electrostatic attraction
post-fabrication may result in dynamic association of cargo, uncontrollable cargo release,
and modification of particle surface properties. Particle Replication in Non-wetting
Templates (PRINT®) technology allows for fabrication of hydrogels with control over size,
shape, composition, surface chemistry, and modulus such that delivery properties may be
tuned to particular applications29-36. Encapsulation of siRNA in hydrogels may be
engineered with PRINT technology, which allows for direct physical entrapment or covalent
incorporation of siRNA during particle fabrication.
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Transfection of cancer cells with siRNA electrostatically entrapped in hydrogels
Initially, a highly cationic, moderately crosslinked hydrogel composition (Table S1) was
pursued to allow for physical entrapment and electrostatic association of siRNA within
cylindrical (diameter [d] = 200 nm; height [h] = 200 nm) PRINT particles prepared by a
film-split technique. To promote cytocompatibility and dispersibility of highly cationic
hydrogel nanoparticles in aqueous media, amine handles on hydrogels were reacted with
succinimidyl succinate monomethoxy PEG2K (Fig. 1a). After PEGylating the hydrogels, a
concomitant decrease in the ζ-potential was observed (Table S2), resulting in a low surface
charge that would be minimally toxic to cell membranes. Steady release of siRNA from the
hydrogel particles in PBS at 37 °C was observed over time, reaching maximum
concentration around 48 h (Fig. 1b). By gel electrophoresis, siRNA loading was determined
to be about 1.4 wt%, and encapsulation efficiency of siRNA in hydrogels was determined to
be ca. 28% (1.4 wt% final siRNA loading in particles relative to the 5 wt% siRNA charged
into the composition of the pre-particle solution). Scanning electron microscopy (SEM)
analysis of the hydrogel particles demonstrates their cylindrical shape and dimensions (Fig.
1c).
To evaluate the transfection potential of particles loaded with siRNA, a stably-transfected,
luciferase-expressing human cervical cancer (HeLa/luc) cell line was utilized for in vitro
studies. Particles were dosed on HeLa cells for 4 h followed by 72 h incubation. Due to the
positive charge of the particles, the PRINT hydrogel particles were readily internalized into
the HeLa cells (Fig. 2a) as determined by flow cytometry. Dose-dependent knockdown of
luciferase expression (Fig. 2b) was observed for HeLa cells incubated with the anti-
luciferase siRNA-charged particles with a half-maximal effective concentration (EC50) of
ca. 6 nM siRNA. Conversely, PRINT hydrogel particles charged with a control siRNA
sequence did not elicit gene knockdown, implying that transfection was sequence-specific
(Fig. 2b). Additionally, both particles were found to be cytocompatible with HeLa cells (Fig.
S1). Confocal microscopy of HeLa cells dosed with PEGylated particles (Fig. 2c,d) shows
the internalization of fluorescent particles and their distribution throughout the cellular
cytoplasm as well as the perinuclear region. Even though the desired cell activity was
achieved with these particles, subsequent efforts to modulate in vivo behavior by
conjugation of targeting ligands to the particle surface resulted in extensive premature
release of siRNA. For example, 50% loss of encapsulated cargo was observed during a
sequence of reactions to add targeting moieties to the particle surface (Fig. S2).
siRNA prodrug for triggered release from hydrogels
In order to combat the premature release issues with the PRINT hydrogel particles described
above, an alternative prodrug strategy was employed which involved covalently conjugating
the siRNA directly to the PRINT hydrogel particles. Acrydite DNA oligonucleotides have
been incorporated into hydrogels for nucleic acid hybridization assays37,38 while a CpG
oligonucleotide methacrylamide has been copolymerized into aciddegradable microparticles
to invoke immune responses39,40. For the triggered release of therapeutic conjugates from
particles or delivery vectors under biologically relevant conditions, acidlabile41-43,
enzymatically degradable44,45, and redox-sensitive linkages46 have been examined.
Glutathione and reducing enzymes are present at high concentrations inside cells relative to
the extracellular space in normal and cancer cell lines47. Considering the serum stability of
disulfide conjugates46,48, cleavage of disulfide linkages in therapeutic conjugates may
selectively occur in the intracellular reducing environment. Disulfide-siRNA conjugates to
polymers and lipids have been previously reported6,7,10-12 as reductively-labile systems.
Dunn et al. Page 3













In this work, siRNA was derivatized with a photopolymerizable acrylate bearing a
degradable disulfide linkage for reversible covalent incorporation into the PRINT hydrogel
nanoparticles (Fig. 3a). In the designed ‘pro-siRNA hydrogels’, it was envisioned that the
siRNA cargo would be retained in the particle until entry of the particle into the cytoplasm
of a cell, where the disulfide linkage would be cleaved in the reducing environment,
allowing for release and delivery of the siRNA (Fig. 3b). A water-based pre-particle
composition containing the disulfide siRNA pro-drug and a higher content of hygroscopic,
liquid monomers (Table S3) was applied to fabricate cylindrical (d = 200 nm; h = 200 nm)
loosely-crosslinked cationic PRINT hydrogel particles using a film-split technique. SEM
micrographs confirmed the dimensions and shape of cylindrical siRNAcontaining particles
(Fig. 3c).
To study the response of pro-siRNA hydrogels to a reducing environment, non-disulfide
acrylamide siRNA-based hydrogel particles and native siRNA-complexed particles were
prepared as controls (Fig. 3a). Release of native siRNA-NH2 occurred rapidly from these
porous, loosely-crosslinked hydrogels (Fig. S4). Fig. S5 showed that different siRNAs were
loaded into hydrogel particles and remained associated with particles directly after
harvesting. Unconjugated siRNA was found in hydrogels charged with native siRNA or
siRNA macromers due to incomplete conversion; therefore, in the following experiments all
particles were extensively washed with 10x PBS to remove the sol fraction containing free
siRNA. The time-dependent release of the siRNA from the pro-drug PRINT hydrogel
particles was evaluated under physiological and reducing conditions (Fig. 4a). The siRNA
was retained in the hydrogel particles over 48 h at 37 °C in PBS while the siRNA was
quickly released from hydrogels when incubated in a reducing environment (5 mM
glutathione), reaching maximum concentration around 4 h (Fig. 4a).
Moreover, the siRNA conjugate did not even leak out of the hydrogel particles when they
were exposed to high salt concentration buffer (10x PBS) at 37 °C for 4 h (Fig. 4b).
Incubation of the non-disulfide, non-degradable acrylamide control siRNA hydrogel
particles did not result in release of the siRNA under reducing conditions as expected.
Stability of the siRNA covalently conjugated to the PRINT hydrogel particles was tested by
incubation of the particles in serum (10% FBS) as a function of time. Over 48 h, the siRNA
in the pro-drug PRINT hydrogel particles could be protected from degradation by RNases
when incubated in serum while siRNA in the form of the simple macromonomer in the
absence of the particle to protect it was rapidly degraded in serum under the same conditions
(Fig. 4c).
pro-siRNA hydrogels for gene silencing
The PRINT particles were designed to have a positive zeta potential to facilitate cell
internalization and endosomal escape by including an amine monomer (AEM, 2-
aminoethylmethacrylate hydrochloride). It is known that excessive amine content in
hydrogels may disrupt and destroy the plasma membrane, eliciting cell death. Conversely,
an insufficient amine content may not enable efficient cell uptake and endosomal escape for
transfection. To optimize cytocompatibility and gene silencing efficiency of pro-siRNA
hydrogels, the AEM content was varied from 5 to 50 wt% (Table S3). Pro-siRNA hydrogels
were not PEGylated as were siRNA-complexed hydrogels whereby the cytocompatibility of
bare particles would be determined. For systemic delivery of particles in vivo, sheddable
coatings that reveal bare particles are attractive to enable targeting and endosomal escape for
effective gene delivery49,50.
ζ-potentials of cationic hydrogels increased with amine content and the Z-average diameters
(Dz) of the resultant particles ranged from 250 to 350 nm (Table 1). Encapsulation of the
siRNA in the hydrogel PRINT particles reached a roughly constant value once the amine
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content was greater than or equal to 20 wt% (Fig. S6). The encapsulation efficiency was
determined to be ca. 35% for AEM contents ≥ 20 wt% while when only using 5% AEM, the
encapsulation was lower (ca. 15%). When the pro-drug, disulfide-containing siRNA
hydrogel PRINT particles were dosed onto luciferase-transfected HeLa cells (HeLa/luc) for
5 h followed by 48 h incubation at 37 °C, dosedependent knockdown of the luciferase
expression was observed (Fig. 5a) for hydrogels with amine contents greater than 5 wt%
AEM. Cytocompatibility was maintained at the lower amine contents and dosing
concentrations (Fig. 5b). It appeared that the 30% AEM-containing PRINT hydrogel
particles provided the ideal combination of gene silencing efficiency (EC50 ~ 20 nM siRNA)
and cytocompatibility (even at high dosing concentrations).
To further investigate the in vitro gene knockdown efficacy of the PRINT hydrogel
particles, the 30% AEM-based hydrogel composition was utilized with four different cargos:
(1) native luc siRNA, (2) degradable disulfide luc siRNA, (3) non-degradable, acrylamide
luc siRNA, and (4) degradable disulfide control siRNA. Zetasizer analysis of the hydrogel
PRINT particles indicated that their size and charge were similar (Table S4) and gel
electrophoresis (Figs. S7) allowed for confirmation of the release of the various cargos.
After dosing the particles on cells and incubating for 48 h, cell viability was maintained
above 80% for all of the samples across all dosing concentrations, except for the particles
charged with the free siRNA (Fig. S8). Uptake of all of the hydrogel particles approached
saturation at around 50 μg/mL particle concentration (Fig. 6a). Dose-dependent silencing of
luciferase expression was elicited notably for the pro-drug, disulfide-based siRNA-
containing hydrogel particles while the control particles did not elicit significant gene
knockdown (Fig. 6b).
The transfection efficiency between siRNA-complexed, PEGylated particles and pro-siRNA
hydrogels is comparable, which can be explained by differences in release characteristics.
PEGylated particles release siRNA slowly in PBS while pro-siRNA hydrogels rapidly
release siRNA under intracellular conditions. Confocal microscopy images of HeLa cells
dosed with particles (Figs. 6c-f) illustrates uptake of the particles, which accumulated
largely in the cytoplasm and perinuclear region. Particles appear significantly brighter in
Figs. 6c-f compared to Figs. 2c,d due to the higher fluorescence intensity emitted by
DyLight 488 compared to fluorescein. Given the internalization of cationic particles by
HeLa cells and distribution throughout the cytoplasm and perinuclear area, potential exists
for the encapsulation of other therapeutic nucleic acids in hydrogel nanoparticles to transfect
diseased cells.
Conclusions
siRNA may be physically or electrostatically entrapped within hydrogel nanoparticles to
provide effective gene knockdown. Nevertheless, to retain cargo during particle
functionalization and under physiological conditions, a covalent incorporation approach was
deemed necessary. To our knowledge, this is the first work to polymerize siRNA in
hydrogel particles for controlled intracellular delivery. The siRNA cargo was found to be
adequately protected by the particles and only released upon reaching the reducing
environment of the cytoplasm for effective gene knockdown. Physical dimensions and
surface functionalization of pro-siRNA hydrogel nanoparticles with targeting and stealthing
ligands are currently under investigation to enable in vivo systemic delivery of siRNAs for
the treatment of diseases.
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2,2′-dithiodiethanol, acryloyl chloride, PEG700 diacrylate, disuccinimidyl carbonate (DSC),
2-aminoethyl methacrylate hydrochloride (AEM), 1-hydroxycyclohexyl phenyl ketone
(HCPK), fluorescein O-acrylate, tetraethylene glycol, and Irgacure 2959 were purchased
from Sigma Aldrich. Poly(vinyl alcohol) 75% hydrolyzed MW ≈ 2 kDa was obtained from
Acros Organics. SS-mPEG2K and PEG1K dimethacrylate were from Polysciences, Inc.
mPEG5K acrylate and SCM-PEG2K-biotin were from Creative PEGWorks. Anti-human
CD71 (Transferrin Receptor) biotinylated OKT9 monoclonal antibody was purchased from
eBioscience. UltraAvidin was obtained from Leinco Technologies. Tetraethylene glycol
monoacrylate (HP4A) was synthesized in-house and kindly provided by Dr. Matthew C.
Parrott, Dr. Ashish Pandya, and Mathew Finniss. PRINT molds were graciously supplied by
Liquidia Technologies. siRNAs were purchased as duplexes from Dharmacon, Inc. Sense
sequence of amine-modified and native anti-luciferase siRNA: 5′-N6-
GAUUAUGUCCGGUUAUGUAUU-3′; anti-sense: 5′- P-
UACAUAACCGGACAUAAUCUU-3′. Sense sequence of amine-modified and native
control siRNA: 5′-N6- AUGUAUUGGCCUGUAUUAGUU-3′; anti-sense: 5′-P-
CUAAUACAGGCCAAUACAUU-3′. All other reagents were obtained from Thermo
Fisher Scientific, Inc. in molecular biology grade or RNase-free when available.
Synthesis of siRNA macromers
Degradable disulfide macromer precursor: 2,2′-dithiodiethanol (15 mL, 0.12 mol) was
dissolved in anhydrous DMF (250 mL) in a 500-mL round-bottomed flask containing NEt3
(20.5 mL, 1.2 eq) under a N2 blanket to which acryloyl chloride (11.0 mL, 1.1 eq) was
added dropwise and allowed to react for 8 h. Crude product was extracted into
dichloromethane against 5% LiCl and purified via silica gel chromatography
(EtOAc:hexanes) to provide monoacrylate-substituted 2,2′-dithiodiethanol (63% yield). 2-
((2hydroxyethyl)disulfanyl)ethyl acrylate (10 g, 48 mmol) was dissolved in anhydrous
acetonitrile (100 mL) in a N2-purged 250mL round-bottomed flask, followed by addition of
disuccinimidyl carbonate (14.8 g, 1.2 eq). The reaction proceeded for 8 h and product was
purified by silica gel chromatography (EtOAc:hexanes 4:1) to afford 2-N-
hydroxysuccinimide, 2′acryloyl-dithiodiethanol as a clear, viscous liquid (82% yield). 1H
NMR (600 MHz, CDCl3) δ = 6.46 (dd, J = 17.4 Hz, 1H), δ = 6.2 (dd, J = 10.7 Hz, 6.8 Hz,
1H), δ = 5.90 (dd, J = 10.7 Hz, 1H), δ = 4.59 (t, J = 6.5 Hz, 2H), δ = 4.45 (t, J = 6.5 Hz, 2H),
δ = 3.05–3.00 (m, J = 6.8 Hz, 4H), δ = 2.87 (s, 4H).
Non-degradable siRNA conjugate precursor: N-hydroxyethyl acrylamide (15 mL, 0.14 mol)
was dissolved with DSC (51.9 g, 1.4 eq) in ACN:DMF 4:1 (250 mL) and reacted for 16 h.
Afterward, ACN was removed via rotary evaporation and product was extracted into EtOAc
against 5% LiCl. Product was concentrated and purified by silica gel column
chromatography (EtOAc:hexanes 4:1) to provide 2-(succinimidyl carbonate)ethyl
acrylamide (80% yield) as a fine white solid. 1H NMR (600 MHz, CDCl3) δ = 6.50 (br, 1H,
NH), δ = 6.34 (dd, J = 17.1 Hz, 1H), δ = 6.19 (dd, J = 10.3 Hz, 6.4 Hz, 1H), δ = 5.71 (dd, J
= 10.3 Hz, 1H), δ = 4.46 (t, J = 5.0, 2H), δ = 3.71 (m, J = 5.5 Hz, 2H), δ = 2.87 (s, 4H).
siRNA macromers: siRNA-NH2 (2 mg, 148 nmol, anti-luciferase siRNA or control
sequence) was dissolved in DEPC-treated PBS (200 μL) in a 1.5-mL RNase-free Eppendorf
tube. Separately, 2N-hydroxysuccinimide, 2′-acryloyl-dithiodiethanol (5.2 mg, 100 eq) or 2-
(succinimidyl carbonate)ethyl acrylamide (3.8 mg, 100 eq) was dissolved in RNase-free
DMF (150 μL) and added to the solution of siRNA. The reaction was allowed to proceed for
36 h where additional 100 eq of the acrylate or acrylamide were added to the reaction
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mixture every 12 h. 5 M NH4OAc (50 μL) and EtOH (1.1 mL) were added to the reaction
mixture, which was vortexed for 15 s. The sample was incubated in a -80 °C freezer for 4 h
followed by centrifugation (14 krpm, 4 °C, 20 min) to pellet the siRNA. The supernatant
was decanted and the pellet was washed twice with 70% EtOH (ice-cold) to provide siRNA
prodrug (79% yield). HR-ESI-MS: m/z found for siRNA sense strand [M-H]− = 6832.366;
m/z calc. for disulfide macromer [M-H]− = 7067.676; found [M-H]− = 7067.855; m/z calc.
for siRNA acrylamide macromer [M-H]− = 6974.506; found [M-H]− = 6974.871.
Characterization of siRNA prodrug precursors was carried out on a 600 MHz Bruker NMR
Spectrometer equipped with a Cryoprobe and siRNA macromonomers were analyzed by an
IonSpec Fourier Transform Mass Spectrometer FTMS (20503 Crescent Bay Drive, Lake
Forest, CA 92630) with a nano electrospray ionization source in combination with a
NanoMate (Advion 19 Brown Road, Ithaca, NY 14850) chip based electrospray sample
introduction system and nozzle operated in the negative ion mode as well as reversed phase
high-performance liquid chromatography (Figs. S9).
Fabrication of hydrogels via PRINT process
Pre-particle solutions were prepared with listed compositions at 2.5 wt% in RNase-free
DMF (for physically entrapped siRNA) or DEPC-treated water containing 0.01 % sodium
dodecyl sulfate (for prodrug siRNA, where all remaining steps were conducted in a humidity
room maintained at 70% relative humidity). Specifically, for each composition, solid and
liquid monomers were dissolved in respective pre-particle solution solvent at a total weight
percent of 2.5%. The film-split technique for preparing particles was performed as described
in the following: using a #5 wire wound rod (R.D.S.), 150 μL of pre-particle solution was
cast at 6 ft/min on a sheet of poly(ethylene terephthalate) (PET), followed by brief
evaporation of solvent with heat gun to yield a transparent film (delivery sheet). 200 × 200
nm cylindrical Fluorocur-patterned PRINT molds (Liquidia Technologies) were laminated
against the delivery sheet with moderate pressure (40 psi) and then gently delaminated. The
filled mold was laminated against corona-treated PET and subsequently cured in a UV
chamber (λmax = 365 nm, 90 mW/cm2) for 5 min. After photocuring, the mold was removed
to reveal an array of particles on PET. Particles were harvested off PET with water
mechanically using a cell scraper (1 mL/48 in2). Particles were washed via centrifugation
(15 min, 14 krpm, 4 °C), removal of supernatant, and re-suspension in water. Particle yield
was determined by thermogravimetric analysis (Q5000IR, TA instruments). Pro-siRNA
hydrogels were washed repeatedly with 10x PBS containing 0.05% PVA 2 kDa to remove
the sol fraction.
Hydrogels with electrostatically-entrapped siRNA were PEGylated by reacting particles
with SS-mPEG2K (2 wt eq, weight equivalents relative to particle mass) using pyridine (2 wt
eq) in DMF at 2 mg/mL particle concentration for 6 h at room temperature followed by
washing particles with water. For post-functionalization of particles with ligands, SCM-
PEG2K-biotin (2 wt eq) was reacted with particles in DMF at 2 mg/mL for 2 h along with
pyridine (4 wt eq). NHS-mPEG12 (2 wt eq) was added to quench non-biotinylated amines
with pyridine (4 wt eq) in DMF at 2 mg/mL for 30 min. Particles were centrifuged, isolated
through removal of supernatant, and washed with PBS. UltraAvidin (0.25 wt eq) was
conjugated to biotinylated particles in PBS at 2 mg/mL for 20 min, followed by
centrifugation, washing with PBS, and adding biotinylated OKT9 antibody (20 wt meq) for
another 20 min at 2 mg/mL, after which particles were washed with PBS to remove
unconjugated antibody and re-suspended in PBS at 2 mg/mL.
Particle characterization
Scanning electron microscropy (SEM) enabled imaging of hydrogels that were dispersed on
a glass slide and coated with 2 nm of Au/Pd (Hitachi S-4700). ζ-potential measurements
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were conducted on 20 μg/mL particle dispersions in 1 mM KCl using a Zetasizer Nano ZS
Particle Analyzer (Malvern Instruments Inc.).
Analysis of siRNA by gel electrophoresis
2.5% agarose gel in TBE buffer was prepared with 0.5 μg/mL ethidium bromide. For
studying release of siRNA from hydrogels, aliquots of particle dispersions were centrifuged
(15 min, 14 krpm, 4 °C) for recovery of the supernatant at various time points and frozen.
Similarly, aliquots of siRNA prodrug incubated in 10% FBS at 37 °C were taken at various
time points and frozen for storage. 12 μL of sample (supernatants from particle dispersions,
siRNA solutions, or particle dispersions) was mixed with 3 μL of 6x loading buffer (60%
glycerol, 0.12 M EDTA in DEPC-treated water) and loaded into the gel. 70 V/cm was
applied for 25 min and the gel was then imaged with ImageQuant LAS 4000 (GE). Analysis
of siRNA band intensity was conducted with Image J software for quantification. siRNA
loading was calculated by comparing the maximum amount of siRNA released to the
particle mass. Encapsulation efficiency of siRNA was calculated by comparing wt% of final
siRNA loading to the siRNA charged into the pre-particle composition (5 wt% of particle).
Cell culture
Luciferase-expressing HeLa cell line (HeLa/luc) was from Xenogen. HeLa/luc cells were
maintained in DMEM high glucose supplemented with 10% FBS, 2 mM L-glutamine, 50
units/mL penicillin and 50 μg/mL streptomycin, 1 mM sodium pyruvate and non-essential
amino acids. All media and supplements were from GIBCO except for FBS which was from
Mediatech, Inc.
In vitro cell uptake analysis
HeLa/luc cells were plated in 96-well plates at 10,000/well and incubated overnight at 37°C.
Cells were dosed with fluorescently-tagged particles in OPTI-MEM at 37 °C (5 % CO2) for
4 h or indicated time for cell uptake studies. Fluorescently-tagged particles were prepared by
incorporation of fluorescent monomers (fluorescein O-acrylate for PEGylated particles and
DyLight 488 maleimide for pro-siRNA particles) in the particle composition and
copolymerization of these monomers into particles matrix. After incubation, cells were
washed and detached by trypsinization. After centrifugation, cells were resuspended in a 0.4
% trypan blue (TB) solution in Dulbecco’s Phosphate Buffers Saline solution (DPBS) to
quench the fluorescein fluorescence from particles associated to the cell surface. Cells were
then washed and resuspended in DPBS or fixed in 1% paraformaldehyde/DPBS, and
analyzed by CyAn ADP flowcytometer (Dako). Cell uptake was represented as percentage
of cells that were positive in fluorescein fluorescence.
In vitro cytotoxicity and luciferase expression assays
HeLa/luc cells were plated in 96-well plate at 10,000/well and incubated overnight at 37°C.
Cells were dosed with particles or Lipofec-tamine 2000/siRNA mix in OPTI-MEM at 37 °C
(5 % CO2) for 4 or 5 h, then particles were removed, and complete grow medium was added
for another 48 h incubation at 37°C. Cell viability was evaluated with Promega CellTiter
96® AQueous One Solution Cell Proliferation Assay, and luciferase expression level was
evaluated with Promega Bright-Glo™ Luciferase Assay according to manufacturer’s
instructions. Light absorption or bioluminescence was measured by a SpectraMax M5 plate
reader (Molecular Devices). The viability or luciferase expression of the cells exposed to
PRINT particles was expressed as a percentage of that of cells grown in the absence of
particles. Half-maximal effective concentration (EC50) of siRNA required to elicit gene
knockdown was determined by applying the dose-dependent gene knockdown data to a
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log(inhibitor) vs. response variable slope non-linear function in GraphPad Prism software
for given siRNA concentrations (calculated from particle concentration and siRNA loading).
Confocal laser scanning microscopy
HeLa/luc cells were plated in 8-well chamber slides (BD) at 10,000/well and incubated
overnight at 37°C. Cells were dosed with green fluorescent particles (fluorescein or DyLight
488 labeled) in OPTI-MEM at 37 °C (5 % CO2) for 4 h. Cells were then washed three times
with PBS, fixed with 4% paraformaldehyde for 10 min, and permeabilized with 0.5%
saponin for 30 min at room temperature. Cells were stained with 100 nM phalloidin-
AlexaFluor 555 for actin for 1 h at room temperature, and then counterstained with 30 μM
DAPI for 15 min. Images were collected with LSM710 confocal laser scanning microscope
(Carl Zeiss).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) Reaction scheme for PEGylation of hydrogels with succinimidyl succinate
monomethoxy PEG2K (SS-mPEG2K), (b) time-dependent release of siRNA from particles
incubated at 2 mg/mL and 37 °C in PBS, and (c) Scanning electron micrograph (SEM) of
particles illustrating their 200×200 nm cylindrical dimensions (scale bar = 2 μm).
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siRNA delivery with PEGylated cationic hydrogels to luciferase-expressing human cervical
cancer (HeLa/luc) cells. (a) Cellular uptake. HeLa/luc cells were dosed with particles for 4 h
followed by trypan blue treatment and flow cytometry analysis. (b) Luciferase expression.
HeLa/luc cells were dosed with particles for 4 h followed by removal of particles and 72 h
incubation in media. Data are representative of at least three independent experiments. The
error bars represent standard deviation from triplicate wells in one experiment. (c) and (d)
Confocal micrographs. HeLa/luc cells were dosed with 50 μg/mL particles containing (c)
luciferase or (d) control siRNA cargos for 4 h. Cellular actin cytoskeleton was stained with
phalloidin (red) and nuclei with DAPI (blue), while particles (green) were labeled with the
fluorescent monomer fluorescein O-acrylate during particle fabrication.
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(a) Structures of degradable and non-degradable siRNA macromers as well as native siRNA,
(b) Illustration of pro-siRNA hydrogel behavior under physiological and intracellular
conditions, and (c) SEM micrograph of pro-siRNA, 200 × 200 nm cylindrical nanoparticles
(scale bar = 2 μm).
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Release profiles and stability of siRNA in 30% AEM-based hydrogels. All hydrogels were
washed with 10x PBS buffer to remove the sol fraction containing unconjugated siRNA
before release studies were performed. (a) Time-dependent incubation of pro-siRNA
hydrogels (1 mg/mL) in PBS and under reducing conditions (glutathione, 5 mM) at 37 °C.
(b) Selective release of the disulfide-coupled siRNA prodrug (PD) from hydrogels under
reducing conditions compared to the acrylamide (AA) macromer and native siRNA (NH2).
Hydrogels were incubated in 10x PBS with or without 5 mM glutathione for 4 h at 1 mg/mL
and 37 °C. (c) Retention of siRNA integrity when conjugated to hydrogels after exposure to
10% fetal bovine serum (FBS) over time. Naked siRNA PD macromer was incubated at 36
ug/mL in 10% FBS for given times, proceeded by storage of solution. pro-siRNA hydrogels
were incubated at 1.2 mg/mL in 10% FBS at 37 °C for given times followed by incubation
in 10x PBS (5 mM glutathione) for 4 h at 1.2 mg/mL and 37 °C to release siRNA.
Differences in siRNA migration observed in gels among the standards and samples which
were released from hydrogels incubated in PBS and 10x PBS may arise from the differences
in salt concentrations of sample solutions.
Dunn et al. Page 15














(a) Luciferase expression and (b) viability of HeLa/luc cells dosed with cationic pro-siRNA
hydrogels fabricated with different amine (AEM) contents. Cells were dosed with particles
for 5 h followed by removal of particles and 48 h incubation in media. Data are
representative of two independent experiments. The error bars represent standard deviation
from triplicate wells in the same experiment. Half maximal effective concentrations (EC50s)
of siRNA (nM) for luciferase gene knockdown are listed in the legend. EC50 was not
available (NA) for hydrogels prepared with 5 wt% AEM due to the absence of dose-
dependent luciferase knockdown.
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30% AEM-based hydrogel particles charged with different siRNA cargos for transfection of
HeLa cells. (a) Cellular uptake. HeLa/luc cells were dosed with particles for 4 h followed by
trypan blue treatment and flow cytometry analysis. (b) Luciferase expression. HeLa/luc cells
were dosed with particles for 4 h followed by removal of particles and 48 h incubation in
media. Data in (a) and (b) represent one of two independent experiments. The error bars
represent standard deviation from triplicate wells in the same experiment. Note that all
hydrogels were thoroughly washed after fabrication to remove non-conjugated siRNA in the
sol fraction. (c)-(f) Confocal micrographs. HeLa/luc cells were dosed with 50 μg/mL
hydrogels containing (c) luc PD (d) luc siRNA-NH2, (e) luc acrylamide, and (f) control PD
siRNA cargos for 4 h. Cellular actin cytoskeleton was stained with phalloidin (red) and
nuclei with DAPI (blue) while particles (green) were labeled with the fluorescent monomer,
DyLight 488 maleimide.
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Table 1
Zetasizer analysis of pro-siRNA hydrogels with variable amine content.
Amine content (wt%) ζ-potential (mV) Dz (nm)
5% AEM +18.2 ± 0.5 350.2 ± 5.4
20% AEM +22.6 ± 0.1 281.6 ± 1.9
25% AEM +27.1 ± 0.3 307.4 ± 6.6
30% AEM +27.9 ± 1.5 324.3 ± 5.6
40% AEM +30.6 ± 1.0 281.3 ± 6.0
50% AEM +34.1 ± 0.4 253.7 ± 3.4
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